{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cosentyx&page=4", "query": { "intervention": "Cosentyx", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 116, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cosentyx&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cosentyx&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T03:48:29.505Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03791060", "title": "Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Necrobiosis Lipoidica Diabeticorum" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "18 Years to 110 Years" }, "enrollment_count": 4, "start_date": "2019-04-03", "completion_date": "2021-04-10", "has_results": true, "last_update_posted_date": "2024-05-17", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03791060" }, { "nct_id": "NCT05080218", "title": "COVID-19 VaccinE Response in Rheumatology Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis", "Psoriatic Arthritis", "Spondylarthritis" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Abatacept", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" }, { "name": "Canakinumab Injection", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jeffrey Curtis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 841, "start_date": "2021-11-15", "completion_date": "2024-05-28", "has_results": false, "last_update_posted_date": "2025-05-02", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05080218" }, { "nct_id": "NCT01132612", "title": "AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Plaque-type Psoriasis" ], "interventions": [ { "name": "AIN457", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2010-05-11", "completion_date": "2016-10-18", "has_results": true, "last_update_posted_date": "2018-01-04", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01132612" }, { "nct_id": "NCT02798211", "title": "Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "Secukinumab 300 mg", "type": "DRUG" }, { "name": "Secukinumab 150 mg", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2016-06-27", "completion_date": "2018-12-05", "has_results": true, "last_update_posted_date": "2021-10-07", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "El Cajon", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02798211" }, { "nct_id": "NCT00928512", "title": "Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Secukinmab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2009-07", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2015-10-30", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 13, "location_summary": "Mesa, Arizona • Peoria, Arizona • Little Rock, Arkansas + 10 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Santa Monica", "state": "California" }, { "city": "Coeur d'Alene", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00928512" }, { "nct_id": "NCT07770646", "title": "A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Axial Spondyloarthritis (AxSpA)" ], "interventions": [ { "name": "Secukinumab (IL-17i )", "type": "DRUG" }, { "name": "Upadacitinib (JAKi)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center, Houston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2026-11-01", "completion_date": "2029-09-15", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07770646" }, { "nct_id": "NCT03589885", "title": "Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plaque Psoriasis" ], "interventions": [ { "name": "Placebo 2 mL auto-injector", "type": "DRUG" }, { "name": "Placebo 1 mL prefilled syringe", "type": "DRUG" }, { "name": "Secukinumab 2 mL auto-injector", "type": "DRUG" }, { "name": "Secukinumab 1 mL prefilled syringe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2018-12-19", "completion_date": "2020-08-05", "has_results": true, "last_update_posted_date": "2021-10-11", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 8, "location_summary": "Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Saint Joseph", "state": "Missouri" }, { "city": "Verona", "state": "New Jersey" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03589885" }, { "nct_id": "NCT02662985", "title": "Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriatic Arthritis" ], "interventions": [ { "name": "AIN457 (secukinumab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2016-08-22", "completion_date": "2020-11-10", "has_results": true, "last_update_posted_date": "2021-12-07", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 4, "location_summary": "Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Wheaton", "state": "Maryland" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02662985" }, { "nct_id": "NCT02696031", "title": "Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-radiographic Spondyloarthritis" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 555, "start_date": "2016-04-29", "completion_date": "2021-03-11", "has_results": true, "last_update_posted_date": "2022-04-29", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02696031" }, { "nct_id": "NCT02074982", "title": "Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Type Psoriasis" ], "interventions": [ { "name": "AIN457 300 mg", "type": "DRUG" }, { "name": "ustekinumab 45/90 mg", "type": "DRUG" }, { "name": "placebo secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 676, "start_date": "2014-02-26", "completion_date": "2016-06-29", "has_results": true, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-11-01T03:48:29.505Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074982" } ] }